Terameprocol - Erimos Pharmaceuticals

Drug Profile

Terameprocol - Erimos Pharmaceuticals

Alternative Names: CINelim; EM-1421; M4N; NSC 136955; Tetra-O-methyl nordihydroguaiaretic acid; Tetra-O-methyl-NDGA; Tetramethoxynordihydroguaiaretic acid; TMNDGA

Latest Information Update: 01 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Erimos Pharmaceuticals
  • Class Antineoplastics; Lignans; Small molecules
  • Mechanism of Action Apoptosis stimulants; BIRC5 protein inhibitors; Cdc2 kinase inhibitors; Mitosis inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Alzheimer's disease; Bacterial infections; Cervical intraepithelial neoplasia; Diabetes mellitus; Haematological malignancies; Head and neck cancer; Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections; Leukaemia; Obesity; Psoriasis; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2018 Phase-I/II development for Glioblastoma is ongoing in USA
  • 03 May 2018 Erimos Pharmaceuticals initiates a phase I trial for Glioblastoma (Recurrent, Metastatic disease, Late stage disease, Second-line therapy or greater) in USA (PO) (NCT02575794)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top